In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than ...

Quantitative techniques based on real-time PCR have been available for leukemia diagnostics for a relatively long time; other innovative methods of molecular quantification are available ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia, or ...

Syndax Pharmaceuticals (NASDAQ:SNDX) fell ~23% in the premarket on Tuesday after the cancer drug developer reported topline data from a pivotal Phase 2 portion of its AUGMENT-101 trial for revumenib, ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...